"JunkDNA" (98.7% of DNA in human) is not "Junk" - requiring a generalization of the "Gene concept". On http://www.junkdna.com website news items are posted (some of them reproduced here from http://www.junkdna.com/new_citations.html ) - to be discussed. My "two cents" is FractoGene (see similar website and upcoming book), a geometrization that has received now experimental support for its first prediction.

Wednesday, June 01, 2005

Affy/Agilent duel - mopping up Intellectual Property

[see the original article at http://www.junkdna.com/new_citations.html ]

NEW YORK, May 31 (GenomeWeb News) -

Affymetrix said today that it plans to acquire privately held ParAllele BioScience for approximately $120 million in stock...

"The potential for ParAllele's technology goes far beyond genotyping," said Stephen Fodor, CEO of Affymetrix...

In 2003, Affy began providing its GeneChip platform for use with ParAllele's genotyping assays, which are based on its Molecular Inversion Probe technology - a process that enables up to tens of thousands of reactions to be multiplexed in a single tube.

Last year, Affy and ParAllele extended the collaboration into a distribution partnership under which ParAllele agreed to design assays for Affymetrix to market for use with the GeneChip platform. ...

posted by Dr. Andras J. Pellionisz at 9:50 AM

1 Comments:

Blogger Dr. Andras J. Pellionisz said...

The Agilent/Affymetrix cut-throat duel is escalating by the day - each mopping up Intellectual Propery left and right. Now we also know the "price tag" of ongoing M/A - measured in hundred millions of dollars per scoop. What is the value of "profile matching in the (obviously) non-Eculidean space?

(parallel genotyping is one issue -the Information Technology to match profiles in a warped hyperspace is another...)

9:56 AM

 

Post a Comment

<< Home